Health Care & Life Sciences » Biotechnology | BioCryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
109.38 M
Public Float
83.54 M
BioCryst Pharmaceuticals Inc.
Stock Exchange NASDAQ Stock Market
EPS
$1
Market Cap
$411.47 M
Shares Outstanding
110.31 M
Public Float
108.28 M

Profile

Address
4505 Emperor Boulevard
Durham North Carolina 27703
United States
Employees -
Website http://www.biocryst.com
Updated 07/08/2019
BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The firm focusses on oral treatments for rare diseases. Its portfolio includes Rapivab, Kallikrein inhibitors, and BCX4430.

Financials

View All

Robert Alexander Ingram
Chairman
Jon P. Stonehouse
President, Chief Executive Officer & Director